Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin in Chinese adults with relapsed or refractory CD22-positive B-cell ALL
CTR20223201Phase 4Completed
- Sponsor
- Wyeth
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Wyeth. Started Dec 2022; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on CTR20223201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223201.